Hyperfine (NASDAQ:HYPR – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its competitors? We will compare Hyperfine to similar businesses based on the strength of its earnings, risk, institutional ownership, analyst recommendations, profitability, dividends and valuation.
Insider & Institutional Ownership
15.0% of Hyperfine shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 26.3% of Hyperfine shares are held by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Hyperfine and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Hyperfine | -156.42% | -91.18% | -55.49% |
| Hyperfine Competitors | -270.28% | -155.47% | -22.38% |
Risk and Volatility
Hyperfine has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Hyperfine’s competitors have a beta of 2.58, indicating that their average share price is 158% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Hyperfine and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Hyperfine | 1 | 1 | 3 | 1 | 2.67 |
| Hyperfine Competitors | 4310 | 10598 | 18377 | 838 | 2.46 |
Hyperfine currently has a consensus price target of $2.02, indicating a potential upside of 221.79%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.32%. Given Hyperfine’s stronger consensus rating and higher probable upside, analysts clearly believe Hyperfine is more favorable than its competitors.
Earnings and Valuation
This table compares Hyperfine and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Hyperfine | $11.40 million | -$35.57 million | -2.10 |
| Hyperfine Competitors | $1.90 billion | $136.81 million | 5.72 |
Hyperfine’s competitors have higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Summary
Hyperfine competitors beat Hyperfine on 7 of the 13 factors compared.
About Hyperfine
Hyperfine, Inc. develops portable magnetic resonance imaging (MRI) technology for brain imaging. Its Swoop system is a low-field MRI scanner designed to bring imaging to patients at the point of care, including settings where access to conventional MRI equipment may be limited. The Swoop system is designed for use near a patient’s bedside and does not require a dedicated MRI suite. The U.S. Food and Drug Administration cleared the system in 2020, marking a milestone for the use of portable MRI in clinical care.
Receive News & Ratings for Hyperfine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperfine and related companies with MarketBeat.com's FREE daily email newsletter.
